Duchenne Muscular Dystrophy (nonsense mutation)

About Tevard Biosciences

Tevard Biosciences is a private, preclinical-stage biotech developing a transformative tRNA platform to treat a wide range of genetic disorders. The company's core technology utilizes suppressor tRNAs to read through premature stop codons (nonsense mutations) and enhancer tRNAs to boost expression of healthy genes, offering a potential one-time cure for diseases like Dravet syndrome, Duchenne muscular dystrophy, and genetic cardiomyopathies. With a leadership team combining deep scientific expertise (including advisors like David Liu and Paul Schimmel) and patient advocacy, Tevard is advancing a pipeline focused on severe CNS and neuromuscular conditions with high unmet need. The company's approach is notable for its ability to target large genes and multiple diseases with a single therapeutic modality.

Therapeutic Areas